Category: Pharmaceutical Industry
-
Moderna, Alnylam settle U.S. COVID vaccine patent infringement dispute
Alnylam has settled its three-year dispute against Moderna in the District of Delaware, after a precedential Federal Circuit decision found the patentee had acted as its own lexicographer in defining a key patent specification term, foreclosing its infringement allegations.
-
Doctrine of equivalents removes painkiller from German market: Grünenthal wins preliminary injunction on appeal
A pharma patent and unfair competition dispute has taken a remarkable turn as the Dusseldorf Higher Regional Court granted a preliminary injunction based on infringement by equivalents.
-
Regeneron makes strides in global Eylea patent enforcement campaign: settles with Sandoz, files fresh UK suits
Regeneron has settled its year-long patent infringement dispute with Sandoz over several patents related to its eye disease drug Eylea, and filed a fresh lawsuit against two more rivals over the same drug in the High Court of Justice for England & Wales.
-
Pfizer, BioNTech hit back against GSK mRNA suits in UPC, Ireland: file UK revocation action
The move does not come as a major surprise, given the pharma companies’ previous success against GlaxoSmithKline in the UK.
-
Post-judgment cleanup orders in UK pharma cases: no disgorgement of Bayer profits; Teva, Glenmark, Generics (UK) recover two thirds of costs
AstraZeneca must reimburse two thirds of the costs of an unsuccessful case Teva, Glenmark and Generics (UK). Separately, Bayer does not have to disgorge profits to Sandoz.
-
Boehringer wins nintedanib PI against Zentiva as UPC CoA reverses Lisbon LD on when infringement is imminent, clarifies how to argue national law
Context: Three months ago, the Unified Patent Court’s (UPC) Lisbon Local Division (LD) denied an application for provisional measures (which in some other jurisdictions would be called a motion for a preliminary injunction (PI)) by Boehringer Ingelheim against Zentiva, holding that an infringement did not appear imminent (item 2 of our May 10, 2025 UPC…
-
BREAKING: GSK cashes in on license deal as CureVac settles U.S. patent dispute with acquirer BioNTech and Pfizer for $790M+
Pfizer and BioNTech have settled their three-year COVID vaccine-related patent infringement dispute with CureVac in the U.S., granting the latter and its licensing partner GSK $370 million each.
-
An interview with Bayer’s outgoing head of IP Dr. Jörg Thomaier, new head Dorian Immler
Following three decades at Bayer, Dr. Jörg Thomaier is retiring as head of IP, super confident that his replacement Dorian Immler will have the energy and drive to make the changes that the department needs to keep prospering.
-
Novo Nordisk suffers loss over negative claim limitation in ongoing patent dispute over diabetes drug Wegovy
The United States District Court for the District of Delaware has ruled that Viatris has not induced the infringement of one of five asserted patents in litigation initiated by Novo Nordisk.
-
U.S. appeals court revokes Novartis short-term injunction in Entresto patent dispute against MSN
Decision allows MSN to launch its generic version of Entresto into the market, and opens the door for others to follow.